FindTrial
Sign In

HLA haploidentical stem cell transplantation using myeloablative regimen including ATG

HLA haploidentical stem cell transplantation using myeloablative regimen including ATG - haplo-full with ATG

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004904
Enrollment
20
Registered
2011-01-20
Start date
2011-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancies

Interventions

HLA haploidentical stem cell transplantation using myeloablative regimen including ATG

Sponsors

Hyogo College of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Written informed consent. 2) Unavailability of HLA (A, B, DR)-matched or -one antigen mismatched-related donor. 3) Unavailability of HLA (A, B, DR)-matched or one allele of HLA-DRB1 mismatched-unrelated donor or needs urgent transplantation. 4) Availability of HLA 2-3 antigen mismatched related donor. 5) In case of hematologic malignancy in an advanced stage, patients could choose an HLA 2-3 antigen-mismatched donor, even if they have an HLA-matched or -1 antigen-mismatched donor. 6) Sufficient organ function 6-1) Ejection Fraction >= 50% 6-2) serum total billirubin is needed to be less than 2.5 times the normal upper limit 6-3) serum creatinine level <= 1.5* upper limit of institution

Exclusion criteria

Exclusion criteria: 1) Allergy for the agents used in conditioning or GVHD prophylaxis 2) Patients who are considered as inappropriate with other reasons

Design outcomes

Primary

MeasureTime frame
survival on day 100—

Secondary

MeasureTime frame
acute GVHD, complications, relapse within three months—

Countries

Japan

Contacts

Public ContactKazuhiro Ikegame

Hyogo College of Medicine Division of Hematology, Department of Internal Medicine

kame@hyo-med.ac.jp0798-45-6886

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026